Mizuho Upgrades Cepheid to Buy | GenomeWeb

NEW YORK (GenomeWeb News) – Investment firm Mizuho late on Thursday upgraded Cepheid to a Buy rating, calling the Sunnyvale, Calif.-based molecular diagnostics firm "a best-in-class diagnostics company."

Analyst Peter Lawson upgraded Cepheid from a Neutral rating, although he lowered estimates to take into account potential lingering issues with the company's manufacturing capabilities, as well as a slower than expected uptake of new products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.